These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 34837321)

  • 1. Biomimetic Nanoparticles Enabled by Cascade Cell Membrane Coating for Direct Cross-Priming of T Cells.
    Chen F; Geng Z; Wang L; Zhou Y; Liu J
    Small; 2022 Jan; 18(3):e2104402. PubMed ID: 34837321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Versatile and Robust Platform for the Scalable Manufacture of Biomimetic Nanovaccines.
    Hu H; Yang C; Zhang F; Li M; Tu Z; Mu L; Dawulieti J; Lao YH; Xiao Z; Yan H; Sun W; Shao D; Leong KW
    Adv Sci (Weinh); 2021 Aug; 8(15):2002020. PubMed ID: 34386315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
    Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
    J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responses.
    Silva M; Silva Z; Marques G; Ferro T; Gonçalves M; Monteiro M; van Vliet SJ; Mohr E; Lino AC; Fernandes AR; Lima FA; van Kooyk Y; Matos T; Tadokoro CE; Videira PA
    Oncotarget; 2016 Jul; 7(27):41053-41066. PubMed ID: 27203391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outer membrane vesicles engineered to express membrane-bound antigen program dendritic cells for cross-presentation to CD8
    Schetters STT; Jong WSP; Horrevorts SK; Kruijssen LJW; Engels S; Stolk D; Daleke-Schermerhorn MH; Garcia-Vallejo J; Houben D; Unger WWJ; den Haan JMM; Luirink J; van Kooyk Y
    Acta Biomater; 2019 Jun; 91():248-257. PubMed ID: 31003032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasmacytoid dendritic cells cross-prime naive CD8 T cells by transferring antigen to conventional dendritic cells through exosomes.
    Fu C; Peng P; Loschko J; Feng L; Pham P; Cui W; Lee KP; Krug AB; Jiang A
    Proc Natl Acad Sci U S A; 2020 Sep; 117(38):23730-23741. PubMed ID: 32879009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineering ApoE3-incorporated biomimetic nanoparticle for efficient vaccine delivery to dendritic cells via macropinocytosis to enhance cancer immunotherapy.
    Zhou S; Huang Y; Chen Y; Liu S; Xu M; Jiang T; Song Q; Jiang G; Gu X; Gao X; Chen J
    Biomaterials; 2020 Mar; 235():119795. PubMed ID: 32014739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy.
    Sánchez-Paulete AR; Teijeira A; Cueto FJ; Garasa S; Pérez-Gracia JL; Sánchez-Arráez A; Sancho D; Melero I
    Ann Oncol; 2017 Dec; 28(suppl_12):xii44-xii55. PubMed ID: 28945841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polyethyleneimine modification of aluminum hydroxide nanoparticle enhances antigen transportation and cross-presentation of dendritic cells.
    Dong H; Wen ZF; Chen L; Zhou N; Liu H; Dong S; Hu HM; Mou Y
    Int J Nanomedicine; 2018; 13():3353-3365. PubMed ID: 29922056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomimetic protein nanoparticles facilitate enhanced dendritic cell activation and cross-presentation.
    Molino NM; Anderson AK; Nelson EL; Wang SW
    ACS Nano; 2013 Nov; 7(11):9743-52. PubMed ID: 24090491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine.
    Hassannia H; Ghasemi Chaleshtari M; Atyabi F; Nosouhian M; Masjedi A; Hojjat-Farsangi M; Namdar A; Azizi G; Mohammadi H; Ghalamfarsa G; Sabz G; Hasanzadeh S; Yousefi M; Jadidi-Niaragh F
    Immunology; 2020 Jan; 159(1):75-87. PubMed ID: 31587253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomimetic nanoparticles for DC vaccination: a versatile approach to boost cancer immunotherapy.
    Meng L; Teng Z; Yang S; Wang N; Guan Y; Chen X; Liu Y
    Nanoscale; 2023 Apr; 15(14):6432-6455. PubMed ID: 36916703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal antibodies targeted against melanoma and ovarian tumors enhance dendritic cell-mediated cross-presentation of tumor-associated antigens and efficiently cross-prime CD8+ T cells.
    Cioca DP; Deak E; Cioca F; Paunescu V
    J Immunother; 2006; 29(1):41-52. PubMed ID: 16365599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immortalized dendritic cell line with efficient cross-priming ability established from transgenic mice harboring the temperature-sensitive SV40 large T-antigen gene.
    Ebihara S; Endo S; Ito K; Ito Y; Akiyama K; Obinata M; Takai T
    J Biochem; 2004 Sep; 136(3):321-8. PubMed ID: 15598888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TRAIL/DR5 plays a critical role in NK cell-mediated negative regulation of dendritic cell cross-priming of T cells.
    Iyori M; Zhang T; Pantel H; Gagne BA; Sentman CL
    J Immunol; 2011 Sep; 187(6):3087-95. PubMed ID: 21832159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leveraging β-Adrenergic Receptor Signaling Blockade for Improved Cancer Immunotherapy Through Biomimetic Nanovaccine.
    Yang C; He Y; Chen F; Zhang F; Shao D; Wang Z
    Small; 2023 Apr; 19(14):e2207029. PubMed ID: 36703529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. β-catenin mediates tumor-induced immunosuppression by inhibiting cross-priming of CD8⁺ T cells.
    Liang X; Fu C; Cui W; Ober-Blöbaum JL; Zahner SP; Shrikant PA; Clausen BE; Flavell RA; Mellman I; Jiang A
    J Leukoc Biol; 2014 Jan; 95(1):179-90. PubMed ID: 24023259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting human dendritic cells via DEC-205 using PLGA nanoparticles leads to enhanced cross-presentation of a melanoma-associated antigen.
    Saluja SS; Hanlon DJ; Sharp FA; Hong E; Khalil D; Robinson E; Tigelaar R; Fahmy TM; Edelson RL
    Int J Nanomedicine; 2014; 9():5231-46. PubMed ID: 25419128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic Cells and Cancer Immunity.
    Gardner A; Ruffell B
    Trends Immunol; 2016 Dec; 37(12):855-865. PubMed ID: 27793569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peritumoral administration of DRibbles-pulsed antigen-presenting cells enhances the antitumor efficacy of anti-GITR and anti-PD-1 antibodies via an antigen presenting independent mechanism.
    Patel JM; Cui Z; Wen ZF; Dinh CT; Hu HM
    J Immunother Cancer; 2019 Nov; 7(1):311. PubMed ID: 31747946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.